Ohio Study Shows Access To Naloxone Soars Without Rx Requirement
JAMA study finds that removing Rx requirement for naloxone in Ohio resulted in a 2,328% increase in orders of the drug dispensed since 2015. Michael Hufford, CEO of a company working on an OTC switch for a naloxone nasal spray, says the results show urgent need for a low-cost OTC product.
You may also be interested in...
Two studies revealed a lack of knowledge by pharmacists in Australia about providing naloxone despite being available without a prescription from pharmacists since 2016. Results could be an indication of potential problems if the opioid antagonist is made available nonprescription in US.
Opposition to making naloxone available OTC remains strident because of stigma surrounding drug overdoses, says Bobby Mukkamala, a head and neck surgeon and an AMA Board of Trustees member.
Up to $6.5m funding will completely cover Harm Reduction Therapeutics' costs for a Phase 1 study, preparation of an NDA and commercial launch production. The study, a standard Phase 1 biocompatibility trial with around 30 subjects, should be completed in a few months later this summer.